Ignite Creation Date:
2024-05-06 @ 6:44 PM
Last Modification Date:
2024-10-26 @ 2:53 PM
Study NCT ID:
NCT05761951
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2023-02-27
Brief Title:
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 DKK1 Inhibitor Leap Therapeutics and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-29
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-01-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-27
First Submit QC Date:
February 27 2023
Study First Post Date:
2023-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-09
Last Update Post Date:
2024-05-13
Last Update Post Date Type:
ACTUAL